Welcome to our dedicated page for Horizon Techn news (Ticker: HRZN), a resource for investors and traders seeking the latest updates and insights on Horizon Techn stock.
Horizon Techn (HRZN) provides venture lending and structured debt solutions to innovation-driven companies across technology, life sciences, healthcare, and related sectors. This news hub offers investors and stakeholders timely access to official updates and strategic developments.
Track all essential HRZN announcements in one location, including earnings reports, partnership agreements, and operational milestones. Our curated collection ensures you stay informed about financing initiatives, portfolio company progress, and industry leadership developments without market speculation.
Key updates cover debt financing arrangements, warrant-related activity, and sector-specific growth initiatives. Bookmark this page for efficient monitoring of Horizon Techn's strategic positioning within specialty finance markets. Regular visits provide critical insights for informed analysis of HRZN's market role and investment profile.
Horizon Technology Finance Corporation (NASDAQ: HRZN) will release its financial results for Q1 2022 after market close on May 3, 2022. A conference call is scheduled for May 4, 2022, at 9:00 a.m. ET, featuring key executives including CEO Robert D. Pomeroy, Jr. Investors can join the call by dialing (877) 407-9716 (domestic) or (201) 493-6779 (international). The call will also be available via a live webcast on the company's website.
Horizon focuses on providing secured loans to venture capital-backed companies in technology, life sciences, and sustainability.
Horizon Technology Finance Corporation (NASDAQ: HRZN) reported a strong Q1 2022, originating $132 million in new loans, with $73 million specifically from HRZN. The company ended the quarter with a record $172 million committed backlog, including $151 million in HRZN commitments. Notably, HRZN also received $12 million in loan prepayments, validating its pricing strategy. The ongoing growth trajectory indicates HRZN's favorable positioning in the specialty finance sector.
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced a $15 million venture loan facility to MyForest Foods Co., funding $7.5 million each from Horizon and a managed private investment vehicle. MyForest Foods specializes in sustainable, whole-cut meat alternatives using mycelium, with the flagship product being MyBacon. The funding aims to support MyForest Foods' growth and working capital, as the company seeks to innovate in the alternative foods market. Horizon's President expressed confidence in MyForest Foods' market potential, highlighting the significance of their unique offerings.
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced that Chairman and CEO Robert D. Pomeroy, Jr. will engage in a fireside chat at the Maxim Group and M-Vest 2022 Virtual Growth Conference on March 30, 2022, at 3:00 p.m. ET. This event aims to showcase insights into the company, which specializes in securing loans for venture-backed firms in technology, life sciences, and sustainability sectors. Interested participants can register for free at the conference's official site.
On March 17, 2022, Horizon Technology Finance Corporation (NASDAQ: HRZN) announced the closure of a $15 million venture loan facility to Secure Transfusion Services, Inc. Horizon funded $5 million of the initial $10 million draw. STS, which operates blood collection centers, aims to modernize the transfusion supply chain and improve blood component availability. The funding is intended for general growth. Horizon's President highlighted STS's potential in addressing the demand for blood platelets.
On March 15, 2022, Horizon Technology Finance Corporation (NASDAQ: HRZN) announced the closure of a $10 million venture loan facility to Aerobiotix, LLC, with Horizon providing $5 million. Aerobiotix specializes in air disinfection systems for healthcare facilities, utilizing ultraviolet technology to eliminate airborne pathogens. The funds will support Aerobiotix's growth and working capital. Horizon's president emphasized the importance of Aerobiotix's technology in improving health outcomes. The investment aligns with Horizon's strategy of backing innovative companies in various sectors.
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced a public offering of 2,500,000 shares at $14.35 each, totaling approximately $35.9 million. The offering is set to close on March 14, 2022, with underwriters having a 30-day option to purchase an additional 375,000 shares. Proceeds will be used to repay outstanding debt from KeyBank, reinvest in accordance with investment goals, and cover operational expenses. Investors are urged to read the preliminary prospectus for detailed information on investment risks and objectives.
Horizon Technology Finance Corporation (Nasdaq: HRZN) announced a proposed underwritten primary offering of 2,500,000 shares of common stock, with an additional option for underwriters to purchase 375,000 shares. The proceeds will primarily repay outstanding debt from its revolving credit facility and will also fund general corporate purposes and operating expenses. The offering is managed by Morgan Stanley, UBS Securities, and Oppenheimer & Co. Investors are advised to review the preliminary prospectus for associated risks and details.
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced monthly cash distributions of $0.10 per share for April, May, and June 2022, totaling $0.30 per share. Since its IPO in 2010, Horizon has paid out $178 million in distributions. The announcements include specific ex-dividend, record, and payment dates for each month. Horizon's board evaluates taxable income for distributions, which may differ from GAAP earnings. The company also offers a Dividend Reinvestment Plan for shareholders to reinvest distributions into additional shares.
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced its fourth-quarter and full-year 2021 financial results, reporting a net investment income of $8.1 million ($0.39/share) for Q4 and a total income of $28.2 million ($1.41/share) for the year, a 36% increase year-over-year. The total investment portfolio reached $458.1 million with a net asset value of $245.3 million ($11.56/share). The company funded 17 loans totaling $79.9 million in Q4 and experienced liquidity events from seven portfolio companies. Monthly distributions of $0.10/share were declared for April, May, and June 2022.
